LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for RBCX on the Spectra Optia Apheresis System. This option gives clinicians ...

The Spectra Optia Apheresis System (Terumo BCT) is an apheresis and cell collection platform which can be used in the treatment of sickle cell disease. The purpose of this evaluation is to assess the ...

Recent peer-reviewed study supports what patients shared with their own voices: Automated red blood cell exchange improves the lives of people struggling with sickle cell disease LAKEWOOD, Colo., Nov.

LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, has entered into a business relationship with Kaneka, a global leader ...

The Agency believes that the ability to manage the cytokine storm associated with COVID-19 may decrease patient morbidity. The Food and Drug Administration (FDA) has issued an Emergency Use ...

LONDON, Feb. 14, 2024 /PRNewswire/ -- Children, young people, and adults across England suffering from sickle cell disease will soon benefit from better care closer to where they live, following the ...

In a significant step toward expanding treatment access for people with rare and chronic diseases in Latin America (LATAM), Terumo Blood and Cell Technologies (Terumo BCT), announced that its Spectra ...

The Agency believes that the ability to manage the cytokine storm associated with COVID-19 may decrease patient morbidity. The Food and Drug Administration (FDA) has issued an Emergency Use ...